FR2805540B1 - NOVEL HUMAN ULIP PROTEIN AND ITS USE IN THE DIAGNOSIS AND THERAPY OF CANCER AND NEUROLOGICAL PARANEOPLASTIC SYNDROMES - Google Patents

NOVEL HUMAN ULIP PROTEIN AND ITS USE IN THE DIAGNOSIS AND THERAPY OF CANCER AND NEUROLOGICAL PARANEOPLASTIC SYNDROMES

Info

Publication number
FR2805540B1
FR2805540B1 FR0002566A FR0002566A FR2805540B1 FR 2805540 B1 FR2805540 B1 FR 2805540B1 FR 0002566 A FR0002566 A FR 0002566A FR 0002566 A FR0002566 A FR 0002566A FR 2805540 B1 FR2805540 B1 FR 2805540B1
Authority
FR
France
Prior art keywords
diagnosis
cancer
therapy
novel human
paraneoplastic syndromes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0002566A
Other languages
French (fr)
Other versions
FR2805540A1 (en
Inventor
Michele Aguera
Jean Christophe Antoine
Marie Francoise Belin
Jerome Honnorat
Veronique Rogemond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0002566A priority Critical patent/FR2805540B1/en
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to DE60121735T priority patent/DE60121735T4/en
Priority to ES01911811T priority patent/ES2269353T3/en
Priority to PCT/FR2001/000589 priority patent/WO2001064737A1/en
Priority to DE60121735A priority patent/DE60121735D1/en
Priority to AT01911811T priority patent/ATE334145T1/en
Priority to CA2401438A priority patent/CA2401438C/en
Priority to US10/220,042 priority patent/US7329499B2/en
Priority to EP01911811A priority patent/EP1263784B1/en
Priority to JP2001564230A priority patent/JP4990459B2/en
Publication of FR2805540A1 publication Critical patent/FR2805540A1/en
Application granted granted Critical
Publication of FR2805540B1 publication Critical patent/FR2805540B1/en
Priority to US12/068,686 priority patent/US8377645B2/en
Priority to US13/741,876 priority patent/US10087220B2/en
Priority to US16/129,279 priority patent/US20190119339A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
FR0002566A 2000-02-29 2000-02-29 NOVEL HUMAN ULIP PROTEIN AND ITS USE IN THE DIAGNOSIS AND THERAPY OF CANCER AND NEUROLOGICAL PARANEOPLASTIC SYNDROMES Expired - Fee Related FR2805540B1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR0002566A FR2805540B1 (en) 2000-02-29 2000-02-29 NOVEL HUMAN ULIP PROTEIN AND ITS USE IN THE DIAGNOSIS AND THERAPY OF CANCER AND NEUROLOGICAL PARANEOPLASTIC SYNDROMES
US10/220,042 US7329499B2 (en) 2000-02-29 2001-02-28 Use of a novel human ULIP6/CRMP protein in diagnosis of paraneoplastic neurological syndromes
PCT/FR2001/000589 WO2001064737A1 (en) 2000-02-29 2001-02-28 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
DE60121735A DE60121735D1 (en) 2000-02-29 2001-02-28 NEW HUMAN ULIP / CRMP PROTEIN AND ITS USE IN DIAGNOSIS FOR THE TREATMENT OF CANCER AND NEUROLOGICAL PARANEOPLASTIC SYNDROME
AT01911811T ATE334145T1 (en) 2000-02-29 2001-02-28 NEW HUMAN ULIP/CRMP PROTEIN AND ITS USE FOR DIAGNOSTIC TREATMENT OF CANCER AND NEUROLOGICAL PARANEOPLASTIC SYNDROME
CA2401438A CA2401438C (en) 2000-02-29 2001-02-28 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
DE60121735T DE60121735T4 (en) 2000-02-29 2001-02-28 New human ULIP / CRMP protein and its use in the diagnosis and treatment of cancers and paraneoplastic neurological syndromes
EP01911811A EP1263784B1 (en) 2000-02-29 2001-02-28 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
JP2001564230A JP4990459B2 (en) 2000-02-29 2001-02-28 Novel human ULIP / CRMP protein and its use in diagnosis and treatment of cancer and paraneoplastic neurological syndrome
ES01911811T ES2269353T3 (en) 2000-02-29 2001-02-28 NEW HUMAN ULIP / CRMP PROTEIN AND ITS USE IN THE DIAGNOSIS AND THERAPY OF CANCERES AND PARANEOPLASIC NEUROLOGICAL SYNDROMES.
US12/068,686 US8377645B2 (en) 2000-02-29 2008-02-11 Diagnosis of cancers and paraneoplastic neurological syndromes with novel human ULIP/CRMP protein
US13/741,876 US10087220B2 (en) 2000-02-29 2013-01-15 Human ULIP/CRMP protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
US16/129,279 US20190119339A1 (en) 2000-02-29 2018-09-12 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0002566A FR2805540B1 (en) 2000-02-29 2000-02-29 NOVEL HUMAN ULIP PROTEIN AND ITS USE IN THE DIAGNOSIS AND THERAPY OF CANCER AND NEUROLOGICAL PARANEOPLASTIC SYNDROMES

Publications (2)

Publication Number Publication Date
FR2805540A1 FR2805540A1 (en) 2001-08-31
FR2805540B1 true FR2805540B1 (en) 2004-04-09

Family

ID=8847550

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0002566A Expired - Fee Related FR2805540B1 (en) 2000-02-29 2000-02-29 NOVEL HUMAN ULIP PROTEIN AND ITS USE IN THE DIAGNOSIS AND THERAPY OF CANCER AND NEUROLOGICAL PARANEOPLASTIC SYNDROMES

Country Status (1)

Country Link
FR (1) FR2805540B1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2829392B1 (en) * 2001-09-07 2005-09-16 Inst Nat Sante Rech Med USE OF CRMPS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH DYSFUNCTION OF THE IMMUNE SYSTEM
US7820375B2 (en) * 2001-09-07 2010-10-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of a protein of the CRMP family for treating diseases related to the immune system
FR2830762B1 (en) * 2001-10-16 2004-10-22 Inst Nat Sante Rech Med USE OF A PROTEIN FROM THE CRMPS FAMILY FOR THE TREATMENT OF IMMUNE SYSTEM-RELATED DISEASES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759701B1 (en) * 1997-02-19 1999-06-04 Inst Nat Sante Rech Med USE OF ULIP PROTEINS IN THE DIAGNOSIS AND THERAPY OF CANCER AND PARANEOPLASTIC NEUROLOGICAL SYNDROMES

Also Published As

Publication number Publication date
FR2805540A1 (en) 2001-08-31

Similar Documents

Publication Publication Date Title
HK1070080A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors
EE200100372A (en) TWEAK Protein and TWEAK Protein Receptor Antagonists and Their Use in the Treatment of Immune Diseases
NO20034855D0 (en) Treatment and diagnosis of macrophage-mediated disease
IS5500A (en) Medicinal preparations for the stimulation and treatment of gastrointestinal disorders and related diseases
IS4416A (en) Body weight modulators, corresponding nucleic acids and proteins, and their use in diagnostic and medical treatment
MXPA05012723A (en) Treatment with anti-vegf antibodies.
NO20014769L (en) Preparation for the treatment and diagnosis of breast cancer and methods for its use
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
ATE198050T1 (en) THERAPEUTIC USES OF BPI PROTEIN PRODUCTS FOR THE TREATMENT OF HUMAN MENINGOCOCCEMIA
DE69728323D1 (en) Variant of the human C3a receptor; diagnostic and therapeutic uses
IL110464A0 (en) Novel proteins for the diagnosis, imaging, and therapy of human cancer
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
TR200103819T2 (en) ET743 compositions and uses in cancer treatment
ID27576A (en) USE OF CYCOSPORINE IN TREATMENT OF AUTOIMUN DISEASE DISEASES
IS6966A (en) Cyano-linked dihydropyrimidine compounds and their use in the treatment of diseases
DE602004020266D1 (en) THERAPEUTIC AND DIAGNOSTIC ANTI-HSP 70 ANTIBODIES
FR2759701B1 (en) USE OF ULIP PROTEINS IN THE DIAGNOSIS AND THERAPY OF CANCER AND PARANEOPLASTIC NEUROLOGICAL SYNDROMES
FR2805540B1 (en) NOVEL HUMAN ULIP PROTEIN AND ITS USE IN THE DIAGNOSIS AND THERAPY OF CANCER AND NEUROLOGICAL PARANEOPLASTIC SYNDROMES
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
FI973185A (en) Use of melatonin in the treatment of patients with drug dependence
FR2807757B1 (en) NOVEL HUMAN ULIP / CRMP PROTEIN AND ITS USE IN THE DIAGNOSIS AND THERAPY OF CANCERS AND NEUROLOGICAL AND PARANEOPLASTIC SYNDROMES
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
EP1322778A4 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
GB9908059D0 (en) Diagnosis and treatment of diseases
ZA9610584B (en) Use of rc-9 in diagnosis and treatment of proliferative arterial disease

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20081031